WELL CONTROLLED ON VIMPAT
If your patient is well controlled and would like to stay on VIMPAT, specify dispense as written (DAW) on prescriptions when appropriate.
VIMPAT is indicated for:
- Treatment of partial-onset seizures in patients 1 month of age and older
Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
IMPORTANT SAFETY INFORMATION
VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.
In the adult adjunctive placebo-controlled trials for partial-onset seizures, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). Pediatric adverse reactions were similar to those seen in adult patients.
Primary Generalized Tonic-Clonic Seizures
In the adjunctive therapy placebo-controlled trial for primary generalized tonic-clonic seizures, the adverse reactions were generally similar to those that occurred in the partial-onset seizures trials. The adverse reactions most commonly reported were dizziness, somnolence, headache, and nausea.
VIMPAT is a Schedule V controlled substance.
A “DAW” DESIGNATION CAN
HELP PATIENTS WHO PREFER TO STAY ON VIMPAT
Many states have a mandatory generic substitution policy. If your well-controlled patients would prefer to stay on
VIMPAT, write DAW-specific language on their prescriptions when appropriate.
For written prescriptions, make sure to specify the DAW language approved in your state. These vary by state, but may include:
- Brand Medically Necessary
- Do Not Substitute
- No Substitution
- May Not Substitute
Not an actual patient
UCB has continued to bring VIMPAT to more patients since it was launched in the U.S. for adult adjunctive therapy for partial-onset seizures in 2009.
IN THE U.S.
Launched for adult
Approved for adult
Approved for monotherapy and adjunctive therapy in
CHILDREN ≥4 YEARS
OF AGE FOR
IN THE TREATMENT OF PGTCS IN PATIENTS 4 YEARS
OF AGE AND OLDER
TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 1 MONTH OF AGE AND OLDER
YEARS OF COMMITMENT TO PATIENTS—AND STILL COUNTING
PATIENT EXPOSURES IN THE U.S. FOR PARTIAL-ONSET SEIZURES1
With VIMPAT, you have administration options. Choose between tablets, oral solution, and intravenous (IV) injection when oral administration is temporarily not feasible.
(Formulations not shown at actual size.)
UCB IS COMMITTED TO TRYING TO HELP MAKE TREATMENT ACCESSIBLE AND AFFORDABLE FOR ELIGIBLE PATIENTS
CONTACT ucbCARES FOR SUPPORT REGARDING UCB
Monday through Friday,
9:00 AM to 6:00 PM ET
Enroll with an e-Rx to the NCPDP
#5910206 (SonexusTM Health Pharmacy)
or fax Rx to 855-338-1386
NCPDP=National Council for Prescription Drug Programs.
1. Data on file. UCB, Inc.
1. Data on file. UCB, Inc.